{"product_id":"johns-hopkins-fourth-annual-retina-festival-2023","title":"Johns Hopkins Fourth Annual Retina Festival 2023","description":"\u003cheader class=\"section__headings section__headings___edc6e\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"field field-name-field-course-summary field-type-text-with-summary field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cdiv class=\"card-header bg-transparent py-4 px-3\"\u003e\n\u003ch5 class=\"product_title entry-title\"\u003eJohns Hopkins Fourth Annual Retina Festival 2023\u003c\/h5\u003e\n\u003cp\u003eJohns Hopkins Fourth Annual Retina Festival 2023\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eInclude: 5 videos + 23 pdfs, size: 6.28 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: ophthalmologist\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Sample video: \u003cspan style=\"color: #0000ff\"\u003e\u003ca style=\"color: #0000ff\" href=\"https:\/\/medustudent.com\/contact_us\/\"\u003econtact me\u003c\/a\u003e\u003c\/span\u003e for sample video\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eDate \u0026amp; Location\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eSaturday, December 2, 2023, 7:00 AM – 5:00 PM, Johns Hopkins School of Medicine, Turner Auditorium, Baltimore, MD\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Ophthalmology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eJohns Hopkins Fourth Annual Retina Festival 2023 The Fourth Annual Retina Festival is an “all-star” line-up of more than 50 faculty members from around the world participating in a Continuing Medical Education event from the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. The program will provide the latest updates from clinical trials and other evidence in the peer-reviewed medical literature that are relevant to the prevention and management of retinal diseases around the world.\u003c\/p\u003e\n\u003cp\u003eJohns Hopkins Fourth Annual Retina Festival 2023\u003c\/p\u003e\n\u003cp\u003eTopics include the latest, clinically relevant outcomes from clinical trials on age-related macular degeneration, vitreomacular interface abnormalities, hereditary retinal degenerations, diabetic retinopathy, retinal vein occlusions, and the latest in retinal surgery, including live retina surgery demonstrations. In addition to presentations from world experts, 4 panels of experts throughout the day will highlight discussions on applying clinical trial results to day-to-day clinical practice. The course should be of interest to comprehensive ophthalmologists, retina specialists both expert and in training, as well as vision scientists who want an update on the latest clinically relevant topics in retina.\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eRecognize the role of anti-angiogenic treatments for eyes with choroidal neovascularization from age-related macular degeneration or diabetic retinopathy, including proliferative diabetic retinopathy and diabetic macular edema.\u003c\/li\u003e\n\u003cli\u003eEvaluate recent clinical studies evaluating treatments for hereditary retinal degenerations.\u003c\/li\u003e\n\u003cli\u003eDiscuss the role of imaging in the management of vitreomacular interface abnormalities.\u003c\/li\u003e\n\u003cli\u003eReview the current and emerging therapeutic approaches for surgical retinal diseases.\u003c\/li\u003e\n\u003cli\u003eSummarize the evidence of surgical and medical treatments for intraocular tumors.\u003c\/li\u003e\n\u003cli\u003eDetermine which patients are appropriate for biologic treatments of posterior uveitis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAtropine for Myopia in the Pediatric Population.pdf\u003c\/li\u003e\n\u003cli\u003eBig Data- Benefits and Limitations When Guiding Clinical Practice.pdf\u003c\/li\u003e\n\u003cli\u003eBiosimilar Agents for Neovascular and Other Retinal Diseases.pdf\u003c\/li\u003e\n\u003cli\u003eCurrent Management of Sickle Cell Retinopathy.pdf\u003c\/li\u003e\n\u003cli\u003eDiabetic Macular Ischemia.pdf\u003c\/li\u003e\n\u003cli\u003eEmerging Treatments for Stargardt Disease and Current Recommendations for Patient Management.pdf\u003c\/li\u003e\n\u003cli\u003eFaricimab or Aflibercept HD for Neovascular AMD.pdf\u003c\/li\u003e\n\u003cli\u003eFaricimab or Aflibercept HD in Diabetic Macular Edema.pdf\u003c\/li\u003e\n\u003cli\u003eFrom Airlie House to ETDRS to DRCR Retina Network in 2022- Imaging NPDR for Risk Factors to Develop PDR.pdf\u003c\/li\u003e\n\u003cli\u003eGene Therapy for Neovascular AMD.pdf\u003c\/li\u003e\n\u003cli\u003eGeographic Atrophy- Primary Outcome Results from Phase 3 Clinical Trials.pdf\u003c\/li\u003e\n\u003cli\u003eGeographic Atrophy- Secondary and Exploratory Outcome Results from Phase 3 Clinical Trials.pdf\u003c\/li\u003e\n\u003cli\u003eImaging Choroidal Neovascularization.pdf\u003c\/li\u003e\n\u003cli\u003eImaging Pathologic Myopia.pdf\u003c\/li\u003e\n\u003cli\u003eIntraocular Tumors.mp4\u003c\/li\u003e\n\u003cli\u003eKeynote Speech- Lessons Learned and Moving Forward with International Collaborations in Retina.pdf\u003c\/li\u003e\n\u003cli\u003eMacular Telangiectasis Treatment Advances.pdf\u003c\/li\u003e\n\u003cli\u003eOther Hot Topics in Retina.mp4\u003c\/li\u003e\n\u003cli\u003ePanel- Clinical Relevance of Geographic Atrophy Clinical Trials.pdf\u003c\/li\u003e\n\u003cli\u003ePathologic Myopia and Central Serous Retinopathy.mp4\u003c\/li\u003e\n\u003cli\u003ePediatric and Inherited Retinal Diseases.mp4\u003c\/li\u003e\n\u003cli\u003ePrevention of Diabetic Retinopathy Worsening.pdf\u003c\/li\u003e\n\u003cli\u003eRefillable Drug Delivery Devices in Common Retinal Diseases.pdf\u003c\/li\u003e\n\u003cli\u003eRetinal Gene Therapy in 2024.pdf\u003c\/li\u003e\n\u003cli\u003eRetinal Vascular Diseases.mp4\u003c\/li\u003e\n\u003cli\u003eRetina_PROGRAM.pdf\u003c\/li\u003e\n\u003cli\u003eThe “Not So Silent” Epidemic of Pathologic Myopia.pdf\u003c\/li\u003e\n\u003cli\u003eUpdates on Voretigene NeparvovecRZYL and Other Agents for Retinal Degenerations.pdf\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e*Detail:\u003c\/p\u003e\n\u003ch3 class=\"boxAgendaTitle\"\u003eSaturday, December 2, 2023\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eWelcome and Conference Goals\u003c\/strong\u003e\u003cbr\u003e\n7:30AM – 7:35AM\u003cbr\u003e\nNeil Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eKeynote Speech: Lessons Learned and Moving Forward with International Collaborations in Retina\u003c\/strong\u003e\u003cbr\u003e\n7:35AM – 7:45AM\u003cbr\u003e\nJ. Fernando Arevalo, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAge-related Macular Degeneration – Geographic and Other Atrophy- MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n7:45AM – 8:45AM\u003cbr\u003e\nEleonora Lad, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAge-related Macular Degeneration – Geographic and Other Atrophy- MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n7:45AM – 8:45AM\u003cbr\u003e\nJames Handa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEmerging Treatments for Stargardt Disease and Current Recommendations for Patient Management\u003c\/strong\u003e\u003cbr\u003e\n7:45AM – 7:55AM\u003cbr\u003e\nMandeep Singh, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGeographic Atrophy: Primary Outcome Results from Phase 3 Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n7:55AM – 8:05AM\u003cbr\u003e\nEleonora Lad, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGeographic Atrophy: Secondary and Exploratory Outcome Results from Phase 3 Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n8:05AM – 8:15AM\u003cbr\u003e\nPeter K Kaiser, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePreclinical Perspectives to Improve Treatment for Geographic Atrophy\u003c\/strong\u003e\u003cbr\u003e\n8:15AM – 8:25AM\u003cbr\u003e\nJames Handa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel: Clinical Relevance of Geographic Atrophy Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n8:25AM – 8:45AM\u003cbr\u003e\nJames Handa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel: Clinical Relevance of Geographic Atrophy Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n8:25AM – 8:45AM\u003cbr\u003e\nMandeep Singh, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel: Clinical Relevance of Geographic Atrophy Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n8:25AM – 8:45AM\u003cbr\u003e\nEleonora Lad, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel: Clinical Relevance of Geographic Atrophy Clinical Trials\u003c\/strong\u003e\u003cbr\u003e\n8:25AM – 8:45AM\u003cbr\u003e\nPeter K Kaiser, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePanel: Clinical Relevance of Geographic Atrophy Clinical Trials -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n8:25AM – 8:45AM\u003cbr\u003e\nNeil Bressler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAge-related Macular Degeneration – Choroidal Neovascularization – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n8:45AM – 10:30AM\u003cbr\u003e\nJ. Fernando Arevalo, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAge-related Macular Degeneration – Choroidal Neovascularization – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n8:45AM – 10:30AM\u003cbr\u003e\nCindy X Cai, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eImaging Choroidal Neovascularization\u003c\/strong\u003e\u003cbr\u003e\n8:45AM – 8:55AM\u003cbr\u003e\nVoraporn Chaikitmongkol, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eGene Therapy for Neovascular AMD\u003c\/strong\u003e\u003cbr\u003e\n8:55AM – 9:05AM\u003cbr\u003e\nPeter A Campochiaro, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBiosimilar Agents for Neovascular and Other Retinal Diseases\u003c\/strong\u003e\u003cbr\u003e\n9:05AM – 9:15AM\u003cbr\u003e\nSophie J Bakri, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRefillable Drug Delivery Devices in Common Retinal Diseases\u003c\/strong\u003e\u003cbr\u003e\n9:15AM – 9:25AM\u003cbr\u003e\nDante Pieramici, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaricimab or Aflibercept HD for Neovascular AMD\u003c\/strong\u003e\u003cbr\u003e\n9:25AM – 9:35AM\u003cbr\u003e\nJudy E Kim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n9:35AM – 10:00AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePathologic Myopia and Central Serous Retinopathy -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n10:30AM – 11:15AM\u003cbr\u003e\nAdam S Wenick, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePathologic Myopia and Central Serous Retinopathy -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n10:30AM – 11:15AM\u003cbr\u003e\nKyoko Ohno-Matsui, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThe “Not So Silent” Epidemic of Pathologic Myopia\u003c\/strong\u003e\u003cbr\u003e\n10:30AM – 10:40AM\u003cbr\u003e\nTien Y Wong, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eImaging Pathologic Myopia\u003c\/strong\u003e\u003cbr\u003e\n10:40AM – 10:50AM\u003cbr\u003e\nKyoko Ohno-Matsui, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRecent Insights into Central Serous Retinopathy\u003c\/strong\u003e\u003cbr\u003e\n10:50AM – 11:00AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n11:00AM – 11:15AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eChoroidal Melanoma Management in 2024\u003c\/strong\u003e\u003cbr\u003e\n11:15AM – 11:25AM\u003cbr\u003e\nCarol L Shields, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntraocular Tumors -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n11:15AM – 12:45PM\u003cbr\u003e\nCarol L Shields, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntraocular Tumors -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n11:15AM – 12:45PM\u003cbr\u003e\nDavid H Abramson, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinoblastoma Management in 2024\u003c\/strong\u003e\u003cbr\u003e\n11:25AM – 11:35AM\u003cbr\u003e\nDavid H Abramson, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n11:35AM – 11:45AM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePediatric and Inherited Retinal Diseases -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n12:45PM – 1:45PM\u003cbr\u003e\nJoseph Anaya, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePediatric and Inherited Retinal Diseases -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n12:45PM – 1:45PM\u003cbr\u003e\nIshrat Ahmed, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUpdates on Voretigene NeparvovecRZYL and Other Agents for Retinal Degenerations\u003c\/strong\u003e\u003cbr\u003e\n12:45PM – 12:55PM\u003cbr\u003e\nWilliam F Mieler, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAtropine for Myopia in the Pediatric Population\u003c\/strong\u003e\u003cbr\u003e\n12:55PM – 1:05PM\u003cbr\u003e\nMichael Repka, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Gene Therapy in 2024\u003c\/strong\u003e\u003cbr\u003e\n1:05PM – 1:15PM\u003cbr\u003e\nByron L Lam, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eManaging ROP in 2024\u003c\/strong\u003e\u003cbr\u003e\n1:15PM – 1:25PM\u003cbr\u003e\nYoshihiro Yonekawa, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n1:25PM – 1:45PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Macular Ischemia\u003c\/strong\u003e\u003cbr\u003e\n1:45PM – 1:55PM\u003cbr\u003e\nSobha Sivaprasad, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Vascular Diseases -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n1:45PM – 3:00PM\u003cbr\u003e\nAdrienne Scott, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRetinal Vascular Diseases -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n1:45PM – 3:00PM\u003cbr\u003e\nJennifer I Lim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMacular Telangiectasis Treatment Advances\u003c\/strong\u003e\u003cbr\u003e\n1:55PM – 2:05PM\u003cbr\u003e\nEmily Chew, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCurrent Management of Sickle Cell Retinopathy\u003c\/strong\u003e\u003cbr\u003e\n2:05PM – 2:15PM\u003cbr\u003e\nJennifer I Lim, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n2:15PM – 2:30PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Retinopathy – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n3:00PM – 3:45PM\u003cbr\u003e\nJun Kong, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDiabetic Retinopathy – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n3:00PM – 3:45PM\u003cbr\u003e\nSophie Cai, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePrevention of Diabetic Retinopathy Worsening\u003c\/strong\u003e\u003cbr\u003e\n3:00PM – 3:10PM\u003cbr\u003e\nRaj Maturi, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFrom Airlie House to ETDRS to DRCR Retina Network in 2022: Imaging NPDR for Risk Factors to Develop PDR\u003c\/strong\u003e\u003cbr\u003e\n3:10PM – 3:20PM\u003cbr\u003e\nJennifer Sun, MD, MPH\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaricimab or Aflibercept HD in Diabetic Macular Edema\u003c\/strong\u003e\u003cbr\u003e\n3:20PM – 3:30PM\u003cbr\u003e\nChristina Y. Weng, MD, MBA\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A\u003c\/strong\u003e\u003cbr\u003e\n3:30PM – 3:45PM\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOther Hot Topics in Retina – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n3:45PM – 5:30PM\u003cbr\u003e\nMira Sachdeva, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOther Hot Topics in Retina – MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n3:45PM – 5:25PM\u003cbr\u003e\nElia Duh, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRecent Advances and Challenges with Artificial Intelligence in Retina\u003c\/strong\u003e\u003cbr\u003e\n3:45PM – 3:55PM\u003cbr\u003e\nJun Kong, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBig Data: Benefits and Limitations When Guiding Clinical Practice\u003c\/strong\u003e\u003cbr\u003e\n3:55PM – 4:05PM\u003cbr\u003e\nCindy X Cai, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEquity, Diversity, and Inclusiveness in Retina\u003c\/strong\u003e\u003cbr\u003e\n4:05PM – 4:15PM\u003cbr\u003e\nAdrienne Scott, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEmerging Treatments for Stargardt Disease and Current Recommendations for Patient Management\u003c\/strong\u003e\u003cbr\u003e\n4:15PM – 4:25PM\u003cbr\u003e\nMandeep Singh, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n4:25PM – 4:55PM\u003cbr\u003e\nMira Sachdeva, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFaculty Commentary and Q\u0026amp;A -MODERATOR\u003c\/strong\u003e\u003cbr\u003e\n4:25PM – 4:55PM\u003cbr\u003e\nElia Duh, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv\u003eJohns Hopkins Fourth Annual Retina Festival 2023\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/header\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954609918050,"sku":"MED-AMB06981","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Johns-Hopkins-600x183-1.jpg?v=1779380593","url":"https:\/\/meducourse.com\/products\/johns-hopkins-fourth-annual-retina-festival-2023","provider":"Meducourse","version":"1.0","type":"link"}